Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Dermatology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 108 articles: HTML format

Single Articles

September 2025
1. TANG X, Khan H, Niewola-Staszkowska K, Wuest F, et al
   Inhibition of autotaxin activity with IOA-289 decreases fibrosis in mouse E0771 breast tumors.
   Int J Cancer. 2025;157:1205-1217.
   PubMed     Abstract available
   
   
   
2. KASPER E, Boulouard F, Basset N, Golmard L, et al
   Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
   Int J Cancer. 2025;157:897-907.
   PubMed     Abstract available
   
   
   
3. LADO-FERNANDEZ P, Vilas JM, Fernandes T, Carneiro C, et al
   Transcriptional repression of SOX2 by p53 in cancer cells regulates cell identity and migration.
   Int J Cancer. 2025;157:980-992.
   PubMed     Abstract available
   
   
   
4. BRITO-ROCHA T, Constancio V, Leite-Silva P, Carvalho-Maia C, et al
   Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.
   Int J Cancer. 2025;157:1006-1019.
   PubMed     Abstract available
   
   
   
5. RABE F, Getachew S, Stroetmann CY, Mezger NCS, et al
   Time to pathologic diagnosis of suspicious breast lesions: An institution-based study in five Ethiopian hospitals.
   Int J Cancer. 2025;157:876-889.
   PubMed     Abstract available
   
   
   
6. HUNTER N, Haylock R
   The risk of basal and squamous cell carcinomas of the skin cancer incidence and external radiation in the updated National Registry for radiation workers cohort in the UK.
   Int J Cancer. 2025 Sep 1. doi: 10.1002/ijc.70096.
   PubMed     Abstract available
   
   
   August 2025
7. RASHID MU, Muhammad N, Arif S, Naeemi H, et al
   Genetic landscape of Pakistani familial breast cancer patients using multigene panel testing.
   Int J Cancer. 2025 Aug 1. doi: 10.1002/ijc.70070.
   PubMed     Abstract available
   
   
   July 2025
8. ZHU J, Huo X, Li X, Yang Z, et al
   Severe cutaneous adverse reactions associated with novel antiandrogens: A disproportionality analysis of three databases.
   Int J Cancer. 2025 Jul 30. doi: 10.1002/ijc.70059.
   PubMed     Abstract available
   
   
   
9. CIVITA P, Mazzanti CM, Lessi F, Marchio C, et al
   Human sporadic breast carcinoma histotypes driven by the Human Betaretrovirus homologous to Mouse Mammary Tumor Virus.
   Int J Cancer. 2025;157:371-383.
   PubMed     Abstract available
   
   
   
10. HOU J, Yang F, Gao Y, Cai H, et al
    MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy.
    Int J Cancer. 2025 Jul 15. doi: 10.1002/ijc.35514.
    PubMed     Abstract available
    
    
    
11. JIA G, Ping J, Tao R, Long J, et al
    Integrating multi-ancestry genomic and proteomic data to identify blood risk biomarkers and target proteins for breast cancer genetic risk loci.
    Int J Cancer. 2025 Jul 14. doi: 10.1002/ijc.70041.
    PubMed     Abstract available
    
    
    June 2025
12. WEI SQ, Leduc V, Potter B, Paradis G, et al
    Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology.
    Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70025.
    PubMed     Abstract available
    
    
    
13. JENSEN A, Gottschau M, Christensen J, Lindquist S, et al
    Risk of breast cancer among women with hypo- and hyperthyroidism: Results from a large nationwide cohort study.
    Int J Cancer. 2025 Jun 23. doi: 10.1002/ijc.70007.
    PubMed     Abstract available
    
    
    
14. MENZ BD, Modi ND, Abuhelwa AY, Kuderer NM, et al
    Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials.
    Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70020.
    PubMed     Abstract available
    
    
    
15. HOVELING LA, Heuken LP, Harfst T, Schuurman MS, et al
    Understanding delays in breast cancer diagnosis in Africa: Key insights and contributing factors.
    Int J Cancer. 2025 Jun 20. doi: 10.1002/ijc.70008.
    PubMed     Abstract available
    
    
    
16. NINMER EK, Zhu H, Chianese-Bullock KA, Slingluff CL Jr, et al
    Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial.
    Int J Cancer. 2025 Jun 19. doi: 10.1002/ijc.70006.
    PubMed     Abstract available
    
    
    
17. MAHAMAT-SALEH Y, Merdas M, Viallon V, Robinot N, et al
    Association of serum metabolites and breast cancer risk: A population-based case-control study in black urban South African women.
    Int J Cancer. 2025 Jun 17. doi: 10.1002/ijc.35503.
    PubMed     Abstract available
    
    
    
18. BENDINELLI B, Danza G, Assedi M, Villanelli F, et al
    Circulating sex hormones and volumetric breast density: A prospective study in women from the EPIC Florence cohort.
    Int J Cancer. 2025;156:2294-2302.
    PubMed     Abstract available
    
    
    
19. POELCHEN J, Pardo S, Novak D, Sun Q, et al
    Generation and functional analysis of melanoma antigen-specific CD8+ T cells derived from S/MAR vector-transfected human induced pluripotent stem cells.
    Int J Cancer. 2025 Jun 12. doi: 10.1002/ijc.35524.
    PubMed     Abstract available
    
    
    
20. MALLARD J, Hucteau E, Schott R, Pivot X, et al
    Tracking cancer-related fatigue during chemotherapy: Insights from a comparative cohort study of early breast cancer patients.
    Int J Cancer. 2025 Jun 10. doi: 10.1002/ijc.35508.
    PubMed     Abstract available
    
    
    
21. MUNHOZ J, Newell M, Bigras G, Goruk S, et al
    Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35517.
    PubMed     Abstract available
    
    
    
22. LAI X, Luan C, Zhang Z, Wessely A, et al
    SOX10, MITF, and microRNAs: Decoding their interplay in regulating melanoma plasticity.
    Int J Cancer. 2025 Jun 3. doi: 10.1002/ijc.35499.
    PubMed     Abstract available
    
    
    
23. NIEDERMAYER K, Schaffler H, Vlachos G, Greco S, et al
    Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35498.
    PubMed     Abstract available
    
    
    
24. BHIMANI J, Wang P, Gallagher GB, O'Connell K, et al
    Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.
    Int J Cancer. 2025 Jun 2. doi: 10.1002/ijc.35494.
    PubMed     Abstract available
    
    
    May 2025
25. LANGSELIUS O, Rumgay H, de Vries E, Whiteman DC, et al
    Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022.
    Int J Cancer. 2025 May 27. doi: 10.1002/ijc.35463.
    PubMed     Abstract available
    
    
    
26. LOAP P, Uakkas A, Bouziane J, Fourquet A, et al
    Long-term cardiac outcomes in breast cancer patients treated with helical tomotherapy: Evaluating the applicability of 3D-based dose constraints for intensity modulated radiation therapy.
    Int J Cancer. 2025 May 23. doi: 10.1002/ijc.35474.
    PubMed     Abstract available
    
    
    
27. XIE X, Chen L, Kong X, Huo Y, et al
    Comparative efficacy and safety of PD-1 versus PD-L1 inhibitors in breast cancer treatment: A systematic review and meta analysis.
    Int J Cancer. 2025;156:1936-1949.
    PubMed     Abstract available
    
    
    
28. KANG NK, Choi KH, Jeong JU, Ahn SJ, et al
    Long-term risk of major cardiac events in breast cancer patients treated with intensity-modulated and 3-dimensional conformal radiotherapy: Secondary analysis of a randomized clinical trial.
    Int J Cancer. 2025 May 9. doi: 10.1002/ijc.35476.
    PubMed     Abstract available
    
    
    
29. WANG Y, He L, Chen M, Chen L, et al
    Timing of surgery and 1-year postoperative outcomes in patients with breast cancer and preoperative COVID-19 history: A matched, longitudinal, ambidirectional cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35466.
    PubMed     Abstract available
    
    
    April 2025
30. CHELLADURAI M, Sagi-Assif O, Ben-Menachem S, Meshel T, et al
    A heterodimer of hemoglobin identifies theranostic targets on brain-metastasizing melanoma cells.
    Int J Cancer. 2025 Apr 26. doi: 10.1002/ijc.35458.
    PubMed     Abstract available
    
    
    
31. MUNOZ CE, Dai WF, Cheung WY, de Oliveira C, et al
    Real-world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan-Canadian population-based cohort study.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35448.
    PubMed     Abstract available
    
    
    
32. STAERK MG, Kaderly Rasmussen EL, Hannibal CG, Hertzum-Larsen R, et al
    Histologically verified penile lichen sclerosus-Incidence in Denmark over 26 years and long-term risk of penile and non-penile cancer.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35454.
    PubMed     Abstract available
    
    
    
33. ANDOUR L, Hagenaars SC, Vangangelt K, Aalberts J, et al
    The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer.
    Int J Cancer. 2025 Apr 15. doi: 10.1002/ijc.35444.
    PubMed     Abstract available
    
    
    
34. GARCIA-SAENZ JA, Spera G, Pollan M, Bermejo B, et al
    Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studi
    Int J Cancer. 2025 Apr 10. doi: 10.1002/ijc.35432.
    PubMed     Abstract available
    
    
    
35. PERRIER F, Ahimbisibwe A, Ghiasvand R, Rueegg CS, et al
    Physical activity and mortality in melanoma patients within the Norwegian Women and Cancer study (NOWAC).
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35430.
    PubMed     Abstract available
    
    
    
36. SCHMIDT ME, Hiensch AE, Depenbusch J, Monninkhof EM, et al
    Impact of exercise on sexual health, body image, and therapy-related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT trial.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35429.
    PubMed     Abstract available
    
    
    
37. LARNDER AH, Manges AR, Murphy RA
    The estrobolome: Estrogen-metabolizing pathways of the gut microbiome and their relation to breast cancer.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35427.
    PubMed     Abstract available
    
    
    
38. HUANG T, Wu D, Jiang L, Wu Z, et al
    Neuro-astrocytic network in breast cancer brain metastases: Adaptive mechanisms and novel therapeutic targets.
    Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35421.
    PubMed     Abstract available
    
    
    
39. PIZZATO M, McCormack V, Dossus L, Al-Alem U, et al
    Education level and risk of breast cancer by tumor subtype in the EPIC cohort.
    Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35413.
    PubMed     Abstract available
    
    
    March 2025
40. LU W, Yao L, Wang Y, Li F, et al
    Characterization of extrachromosomal circular DNA associated with genomic repeat sequences in breast cancer.
    Int J Cancer. 2025 Mar 26. doi: 10.1002/ijc.35423.
    PubMed     Abstract available
    
    
    
41. VIRAZELS M, Lusque A, Brayer S, Genais M, et al
    TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFalpha clinical study.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35416.
    PubMed     Abstract available
    
    
    
42. JALAGUIER S, Kuehn A, Petitpas C, Dulom A, et al
    The transcription factor RIP140 regulates interferon gamma signaling in breast cancer.
    Int J Cancer. 2025 Mar 10. doi: 10.1002/ijc.35405.
    PubMed     Abstract available
    
    
    February 2025
43. SCHWERD-KLEINE P, Wurth R, Cheytan T, Michel L, et al
    Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility.
    Int J Cancer. 2025 Feb 28. doi: 10.1002/ijc.35386.
    PubMed     Abstract available
    
    
    January 2025
44. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    PubMed     Abstract available
    
    
    
45. GOLANI R, Kagenaar E, Jegu J, Belot A, et al
    Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.
    Int J Cancer. 2025 Jan 24. doi: 10.1002/ijc.35320.
    PubMed     Abstract available
    
    
    
46. ZHOU J, Qiu T, Zhang Z, Lan Y, et al
    Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35344.
    PubMed     Abstract available
    
    
    
47. ZAHWE M, Bendahhou K, Eser S, Mukherji D, et al
    Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022.
    Int J Cancer. 2025 Jan 10. doi: 10.1002/ijc.35325.
    PubMed     Abstract available
    
    
    
48. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    PubMed     Abstract available
    
    
    December 2024
49. RODRIGUEZ MS, Mahmoud YD, Vanzulli S, Giulianelli S, et al
    FGFR2-RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression.
    Int J Cancer. 2024 Dec 28. doi: 10.1002/ijc.35302.
    PubMed     Abstract available
    
    
    
50. KOUVARAKI M, Zerdes I, Sifakis EG, Sarafidis M, et al
    Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.
    Int J Cancer. 2024 Dec 27. doi: 10.1002/ijc.35319.
    PubMed     Abstract available
    
    
    
51. THILL M, Zahn MO, Welt A, Nusch A, et al
    Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296.
    PubMed     Abstract available
    
    
    
52. MOUHANNA P, Stahlberg A, Andersson D, Albu-Kareem A, et al
    Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements.
    Int J Cancer. 2024 Dec 18. doi: 10.1002/ijc.35292.
    PubMed     Abstract available
    
    
    
53. CHENG TC, Huang BM, Liao YC, Chang HS, et al
    Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35271.
    PubMed     Abstract available
    
    
    
54. CHEN Y, Salas LA, Marotti JD, Jenkins NP, et al
    Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35274.
    PubMed     Abstract available
    
    
    November 2024
55. HOANG T, Lee J, Jung SY, Kim J, et al
    Determining risk-adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors.
    Int J Cancer. 2024 Nov 27. doi: 10.1002/ijc.35265.
    PubMed     Abstract available
    
    
    
56. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    PubMed     Abstract available
    
    
    
57. LI T, Zhang M, Zhang T, Li S, et al
    Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255.
    PubMed     Abstract available
    
    
    
58. CAO L, Ou D, Qi WX, Xu C, et al
    A randomized trial of early cardiotoxicity in breast cancer patients receiving postoperative IMRT with or without serial cardiac dose constraints.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35245.
    PubMed     Abstract available
    
    
    
59. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available
    
    
    October 2024
60. HOLDER EX, Bigham Z, Nelson KP, Barnard ME, et al
    Mammographic density and breast cancer risk among Black American women.
    Int J Cancer. 2024 Oct 19. doi: 10.1002/ijc.35223.
    PubMed     Abstract available
    
    
    
61. ARIBAL E, Seker ME, Guldogan N, Yilmaz E, et al
    Value of automated breast ultrasound in screening: Standalone and as a supplemental to digital breast tomosynthesis.
    Int J Cancer. 2024;155:1466-1475.
    PubMed     Abstract available
    
    
    
62. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
    Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
    Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
    PubMed     Abstract available
    
    
    
63. HAMAD W, Michell MJ, Myles JP, Gilbert FJ, et al
    Diagnostic performance of tomosynthesis plus synthetic mammography versus full-field digital mammography with or without tomosynthesis in breast cancer screening: A systematic review and meta-analysis.
    Int J Cancer. 2024 Oct 12. doi: 10.1002/ijc.35217.
    PubMed     Abstract available
    
    
    
64. QIU T, Xiang S, Zhou J, Yang M, et al
    Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance.
    Int J Cancer. 2024 Oct 6. doi: 10.1002/ijc.35207.
    PubMed     Abstract available
    
    
    September 2024
65. KE C, Chen M, Lin L, Huang Y, et al
    Postmarketing adverse events of tamoxifen in male and female patients with breast cancer.
    Int J Cancer. 2024 Sep 21. doi: 10.1002/ijc.35193.
    PubMed     Abstract available
    
    
    
66. PFOB A, Surovtsova I, Kokh DB, Heil J, et al
    Use of chemotherapy and loco-regional therapy in stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study.
    Int J Cancer. 2024 Sep 18. doi: 10.1002/ijc.35189.
    PubMed     Abstract available
    
    
    
67. BARNES I, Garcia-Closas M, Gathani T, Sweetland S, et al
    A comparative analysis of risk factor associations with interval and screen-detected breast cancers: A large UK prospective study.
    Int J Cancer. 2024;155:979-987.
    PubMed     Abstract available
    
    
    
68. KOON SUN PAT M, Manraj M, Manraj S
    Breast cancer survival analysis in the Republic of Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35172.
    PubMed     Abstract available
    
    
    
69. POISEUIL M, Molinie F, Dabakuyo-Yonli TS, Laville I, et al
    Impact of organized and opportunistic screening on excess mortality and on social inequalities in breast cancer survival.
    Int J Cancer. 2024 Sep 7. doi: 10.1002/ijc.35173.
    PubMed     Abstract available
    
    
    August 2024
70. PERERA MM, Smit AK, Smith AL, Gallo B, et al
    Adherence to melanoma screening and surveillance skin check schedules tailored to personal risk.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35146.
    PubMed     Abstract available
    
    
    
71. LIU B, Song Y, Xu Y, Sun Q, et al
    Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35140.
    PubMed     Abstract available
    
    
    
72. KIM CE, Pereira A, Binder AM, Amarasiriwardena C, et al
    Time-specific impact of trace metals on breast density of adolescent girls in Santiago, Chile.
    Int J Cancer. 2024;155:627-636.
    PubMed     Abstract available
    
    
    
73. KINDT CK, Alves CL, Ehmsen S, Kragh A, et al
    Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
    Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35126.
    PubMed     Abstract available
    
    
    July 2024
74. LEREVEREND C, Kotaich N, Cartier L, De Boni M, et al
    Enhanced expression of galectin-9 in triple negative breast cancer cells following radiotherapy: Implications for targeted therapy.
    Int J Cancer. 2024 Jul 30. doi: 10.1002/ijc.35107.
    PubMed     Abstract available
    
    
    
75. FORSCHNER A, Nanz L, Maczey-Leber Y, Amaral T, et al
    Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition.
    Int J Cancer. 2024 Jul 20. doi: 10.1002/ijc.35103.
    PubMed     Abstract available
    
    
    
76. KADERLY RASMUSSEN EL, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35101.
    PubMed     Abstract available
    
    
    
77. GABRIELSON M, Hammarstrom M, Bergqvist J, Lang K, et al
    Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
    Int J Cancer. 2024;155:339-351.
    PubMed     Abstract available
    
    
    
78. TURNER JA, Van Gulick RJ, Robinson WA, Mughal T, et al
    Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
    Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35087.
    PubMed     Abstract available
    
    
    
79. JIANG C, Giaquinto AN, Jemal A, Sung H, et al
    Trends in breast cancer incidence by estrogen receptor status in the United States, 2004-2020.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35073.
    PubMed     Abstract available
    
    
    
80. WOHLFEIL SA, Kranzmann L, Weiss C, von Wasielewski I, et al
    Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
    Int J Cancer. 2024 Jul 8. doi: 10.1002/ijc.35078.
    PubMed     Abstract available
    
    
    
81. BHIMANI J, O'Connell K, Persaud S, Blinder V, et al
    Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
    Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053.
    PubMed     Abstract available
    
    
    June 2024
82. BLOEM M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, et al
    Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
    Int J Cancer. 2024 Jun 24. doi: 10.1002/ijc.35060.
    PubMed     Abstract available
    
    
    
83. FODA BM, Misek SA, Gallo KA, Neubig RR, et al
    Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade.
    Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35056.
    PubMed     Abstract available
    
    
    
84. KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al
    Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
    Int J Cancer. 2024;154:2176-2188.
    PubMed     Abstract available
    
    
    
85. ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al
    Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre-tumorous alterations and is associated with adverse outcomes.
    Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050.
    PubMed     Abstract available
    
    
    May 2024
86. DE JONGE C, Schipper RJ, Walstra CJEF, Van Riet YE, et al
    Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35033.
    PubMed     Abstract available
    
    
    
87. HAN X, Liu Y, Zhang S, Li L, et al
    Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
    Int J Cancer. 2024;154:1802-1813.
    PubMed     Abstract available
    
    
    
88. HWANG HW, Shin HT, An HY, Byun JW, et al
    Genomic progression for local invasion of cutaneous squamous cell carcinoma from the superficial to the deep portion.
    Int J Cancer. 2024 May 13. doi: 10.1002/ijc.34952.
    PubMed     Abstract available
    
    
    
89. BAO Y, Sui X, Wang X, Qu N, et al
    Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
    PubMed     Abstract available
    
    
    April 2024
90. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
    Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
    PubMed     Abstract available
    
    
    
91. KNUUTILA JS, Riihila P, Nissinen L, Heiskanen L, et al
    Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma.
    Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34957.
    PubMed     Abstract available
    
    
    
92. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
93. FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al
    PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
    Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947.
    PubMed     Abstract available
    
    
    
94. LIN YY, Gao HF, Li H, Hu Q, et al
    Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
    PubMed     Abstract available
    
    
    
95. WANG Y, Cai W, He P, Cai Q, et al
    Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
    PubMed     Abstract available
    
    
    March 2024
96. WU H, Wang W, Zhang Y, Chen Y, et al
    Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
    PubMed     Abstract available
    
    
    
97. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
    Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
    PubMed     Abstract available
    
    
    
98. DAL MASO L, Toffolutti F, De Paoli A, Giudici F, et al
    Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population-based study in Italy.
    Int J Cancer. 2024 Mar 23. doi: 10.1002/ijc.34923.
    PubMed     Abstract available
    
    
    
99. BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927.
    PubMed     Abstract available
    
    
    
100. WANG T, Chai B, Chen WY, Holmes MD, et al
     Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
     Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
     PubMed     Abstract available
     
     
     
101. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
     Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
     Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
     PubMed     Abstract available
     
     
     
102. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
     Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
     Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
     PubMed     Abstract available
     
     
     
103. LIU X, Xie X, Sui C, Liu X, et al
     Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
     Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
     PubMed     Abstract available
     
     
     February 2024
104. TANG T, Yu H, Xu S, Zhong Y, et al
     Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
     Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
     PubMed     Abstract available
     
     
     
105. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
     Age-related phenotypes in breast cancer: A population-based study.
     Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
     PubMed     Abstract available
     
     
     January 2024
106. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
     SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
     Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
     PubMed     Abstract available
     
     
     
107. SHARMA MP, Shukla S, Misra G
     Recent advances in breast cancer cell line research.
     Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849.
     PubMed     Abstract available
     
     
     
108. CHEN H, Yang G, Ma J
     Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
     Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.